The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 23, 2025

Filed:

May. 27, 2016
Applicant:

Electrophoretics Limited, London, GB;

Inventors:

Ian Hugo Pike, Cobham, GB;

Malcolm Andrew Ward, Cobham, GB;

Claire Louise Russell, Cobham, GB;

Vikram Mitra, Cobham, GB;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/437 (2006.01); A61K 31/13 (2006.01); A61K 31/445 (2006.01); A61K 31/55 (2006.01); A61K 31/57 (2006.01); A61P 25/28 (2006.01); C07K 14/47 (2006.01); C12N 9/16 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
A61K 31/437 (2013.01); A61K 31/13 (2013.01); A61K 31/445 (2013.01); A61K 31/55 (2013.01); A61K 31/57 (2013.01); A61P 25/28 (2018.01); C07K 14/4711 (2013.01); C12N 9/16 (2013.01); G01N 33/6896 (2013.01); G01N 2800/2821 (2013.01); G01N 2800/50 (2013.01); G01N 2800/56 (2013.01);
Abstract

The invention relates to panels of biomarkers including proteins phosphatase 1 regulatory subunit 14A and/or 2',3′-cyclic-nucleotide 3′-phosphodiesterase and/or phosphorylated tau or fragments thereof and methods using thereof for diagnosing, staging, treating and assessing the response of a treatment for a neurocognitive disorder characterised by tau toxicity, in particular for Alzheimer's disease. The present invention shows that the biomarkers disclosed herein are elevated in the brain of subjects with an advanced stage of a neurocognitive disorder (Braak stage V/VI) and/or are regulated in the CSF of AD subjects in comparison to cognitively affected non-AD controls; and/or regulated in response to two casein kinase 1 delta inhibitors.


Find Patent Forward Citations

Loading…